Butamaj Inj.

Description

Composition: 

Each 1 ml contains: 

Buparvaquone : 50 mg 

 Properties: 

• Buparvaquone is a second-generation hydroxynaphthoquinone related to parvaquone, its used for the therapy and prophylaxis of all forms of theileriosis. 

• Long plasma half-life (at least 7 days). 
• Low toxicity: oral LD50 in rats > 8000 mg/kg 

 Indications: 

• Butamaj Inj. is indicated for the treatment of theileriosis (East Coast Fever, Corridor disease, Tropical theileriosis, etc) in cattle caused by Theileria parva, T. annulata, T. mutans, and T. orientalis. 
• It is active against both the Schizonts and piroplasms stages of theileria and may be used during the incubation period of the disease or when clinical signs are apparent. 

 Dosage and administration: 

Administered by intramuscular injection into the neck muscles.  

Butamaj Inj. is administered as a single dose at the rate of 1ml per 20kg bodyweight (equivalent to 2.5mg buparvaquone/ kg bodyweight).  

• In severe and advanced cases, a second treatment may be required at 48-72 hours after the initial injection at the same dose rate.  
• Avoid wet or dirty areas of the skin.  
• Not more than 10 ml should be injected into a single site. 

 Warnings and Precautions: 

• Butamaj Inj. should   never   be   given   by   intravenous   or subcutaneous injection. 
• Localised, painless, oedematous swelling may occasionally be at the injection site. 

• Theileriosis has severe depressant effects on the immune system. Therefore, it is recommended that any vaccination be delayed until the animal has recovered. 

 Withdrawal period: 

• Animals should not be slaughtered for human consumption during treatment and within 42 days from the last treatment.
• Milk from treated cattle should not be used for human consumption during treatment and within 48 hours from the last treatment. 

 Storage: 

Store at a temperature below 30oC.